Low serum MMP-1 in breast cancer: A negative prognostic factor

Biomarkers

Volumn 17, Issue 5, 2012, Pages 416-421

  Kulic A ^a   Dedic Plavetic N ^a,b   Vrbanec, J ^b   Sirotkovic Skerlev M ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

Author keywords

Clinicopathological correlation; Prognosis; Proteases

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERSTITIAL COLLAGENASE;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84864575062     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.678885     Document Type: Article

References (29)

1. Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V. (2003). Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human reast cancer model. Differentiation 71:114-125.
2. Boström P, Söderström M, Vahlberg T, Söderström KO, Roberts PJ, Carpén O, Hirsimäki P. (2011). MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer 11:348.
3. Cancer registry. Croatian National Institute for Public Health, 2010.
4. Available at. http://www.hzjz.hr/rak/novo.htm Accessed on 28 February 2011.
5. Decock J, Hendrickx W, Vanleeuw U, Van Belle V, Van Huffel S, Christiaens MR, Ye S, Paridaens R. (2008). Plasma MMP1 and MMP8 expression in breast cancer: Protective role of MMP8 against lymph node metastasis. BMC Cancer 8:77.
6. Egeblad M, Werb Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174.
7. Fingleton B. (2006). Matrix metalloproteinases: Roles in cancer and metastasis. Front Biosci 11:479-491.
8. Fingleton B. (2007). Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 13:333-346.
9. Folkman J. (2004). Endogenous angiogenesis inhibitors. APMIS 112:496-507.
10. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. (1994). Matrix metalloproteinases degrade insulin-like growth factorbinding protein-3 in dermal fibroblast cultures. J Biol Chem 269:25742-25746.
11. Ghosh AK, Bhattacharyya S, Varga J. (2004). The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem 279:47455-47463.
12. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: The next generation. Cell 144:646-674.
13. Horwitz KB, McGuire WL. (1977). Progesterone and progesterone receptors in experimental breast cancer. Cancer Res 37:1733-1738.
14. Mañes S, Llorente M, Lacalle RA, Gómez-Moutón C, Kremer L, Mira E, Martínez-A C. (1999). The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem 274:6935-6945.
15. Marsolais D, Côté CH, Frenette J. (2007). Pifithrin-Alpha, an inhibitor of p53 transactivation, alters the inflammatory process and delays tendon healing following acute injury. Am J Physiol Regul Integr Comp Physiol 292:R321-R327.
16. Martin MD, Matrisian LM. (2007). The other side of MMPs: Protective roles in tumor progression. Cancer Metastasis Rev 26:717-724.
17. Mbeunkui F, Johann DJ Jr. (2009). Cancer and the tumor microenvironment: A review of an essential relationship. Cancer Chemother Pharmacol 63:571-582.
18. McGowan PM, Duffy MJ. (2008). Matrix metalloproteinase expression and outcome in patients with breast cancer: Analysis of a published database. Ann Oncol 19:1566-1572.
19. McQuibban GA, Gong JH, Wong JP, Wallace JL, Clark-Lewis I, Overall CM. (2002). Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100:1160-1167.
20. Montel V, Kleeman J, Agarwal D, Spinella D, Kawai K, Tarin D. (2004). Altered metastatic behavior of human breast cancer cells after experimental manipulation of matrix metalloproteinase 8 gene expression. Cancer Res 64:1687-1694.
21. Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel M. (2001). Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111-118.
22. Remacle AG, Noël A, Duggan C, McDermott E, O'Higgins N, Foidart JM, Duffy MJ. (1998). Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77:926-931.
23. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. (1999). Proteolytic control of growth factor availability. APMIS 107:80-85.
24. Sternlicht MD, Werb Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463-516.
25. Turpeenniemi-Hujanen T. (2005). Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 87:287-297.
26. Vihinen P, Kähäri VM. (2002). Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 99:157-166.
27. Vu TH, Werb Z. (2000). Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev 14:2123-2133.
28. Watson SA, Tierney G. (1998). Matrix metalloproteinase inhibitors: A review. BioDrugs 9:325-335.
29. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S. (1999). Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 878:212-227.